This website is an international information resource intended for international healthcare professionals outside the United States of America (US) and the United Kingdom (UK) who are interested in information about Boehringer Ingelheim oncology.
While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that compound status or the registration status and approved product labels of the products described within this website may not be the same in different countries.
Information about approved products on this website is derived from the Summary of Product Characteristics (SPC) for each product in the EU. It is not country-specific and may vary from the approved label in the country where you are located. Please refer to your local Prescribing Information for full details.
By clicking on the link below you are declaring and confirming that you are a healthcare professional outside the United States of America and the United Kingdom and have read and understood this disclaimer.
This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information
PK/PD properties of BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking Nanobody®, in patients (pts) with advanced/metastatic solid tumors
Christophe Le Tourneau, Josep Tabernero, Rainer Claus, Ralph Fritsch, Francesco Ricci, Elena Elez, Björn Hackanson, Thomas Arnhold, Sascha Keller, Ralph Graeser, Nicolas Isambert
FOR HEALTHCARE PROFESSIONALS ONLY.
In the European Union, afatinib is approved for use in TKI-naive adults with locally advanced or metastatic NSCLC with activating EGFR mutations and in patients with NSCLC of squamous histology on or after chemotherapy. It is not yet approved in other indications.
